GlassScriptPhysician profile
John P Connolly
NPI 1821000480
$10,187.12
in general payments reported to CMS, 2019-2025
33 companies · $483 in 2025
The $483 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,885 · 2020: $1,655 · 2021: $1,731 · 2022: $2,262 · 2023: $2,158 · 2024: $14.11 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.55 |
| Education | $244.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,471.50 | 2019-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $1,442.00 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,286.62 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Actelion Pharmaceuticals US, INC. | $631.19 | 2019-2023 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $613.60 | 2019-2023 | Yupelri |
| Grifols USA, LLC | $501.57 | 2019-2023 | Prolastin-C Liquid |
| United Therapeutics Corporation | $500.47 | 2019-2023 | Orenitram, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $483.71 | 2021-2023 | Dupixent |
| Genzyme Corporation | $388.44 | 2019-2025 | |
| Electromed, INC. | $345.29 | 2022-2023 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $293.16 | 2020-2023 | Glassia, Hyqvia |
| Advanced Respiratory, INC | $273.00 | 2019-2021 | |
| Philips North America LLC | $267.77 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $256.35 | 2019-2020 | |
| Insmed, INC. | $214.16 | 2019-2023 | Arikayce |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $192.58 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.66 | 2020-2022 | |
| Pfizer INC. | $139.68 | 2019-2023 | |
| Amgen INC. | $124.47 | 2023-2025 | Tezspire |
| Astellas Pharma US INC | $109.91 | 2023 | Cresemba, Ambisome |
| Baxter Healthcare | $105.34 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Csl Behring | $63.37 | 2021-2023 | Hizentra |
| Paratek Pharmaceuticals, INC. | $56.76 | 2019-2021 | |
| Shire North American Group INC | $51.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.27 | 2022-2023 | Airduo Digihaler |
| Merck Sharp & Dohme LLC | $30.73 | 2019-2023 | |
| Gilead Sciences, INC. | $29.53 | 2019-2021 | |
| Akcea Therapeutics, INC. | $25.42 | 2019 | |
| Covis Pharma Gmbh | $22.73 | 2022 | |
| Verona Pharma, INC. | $22.51 | 2025 | Ohtuvayre |
| Circassia INC. | $19.46 | 2019 | |
| Genentech USA, INC. | $17.53 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Connolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.